TECHNOLOGY: Boston Sci winning the latest battle in the Stent war

The latest battle in the cardiology war between drug-eluting stents seems to be going decisively to Boston Scientific. Their Taxus stent has barely been on the market for a few weeks and it’s already burning up the charts, already selling at an equivalent annual clip of over $1.2 billion. On the same day that their stock rallied on the good news its competitor J&J’s Cypher is having the dreaded production quality problems. That type of shooting yourself in the foot problem plagued Schering Plough in its recent downturn, and can take a while to sort out. By no means is a company of J&J’s size and reputation going to let this continue, and because of J&J’s overall size it won’t make too much of an impact on its stock price, but for the moment this round is clearly being won by the other side.

Spread the love

Categories: Uncategorized

Tagged as:

Leave a Reply

Your email address will not be published.